|
1
|
Kanwar J, Taskeen M, Mohammad I, Huo C,
Chan TH and Dou QP: Recent advances on tea polyphenols. Front
Biosci (Elite Ed). 4:111–131. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jin L, Li C, Xu Y, Wang L, Liu J, Wang D,
et al: Epigallocatechin gallate promotes p53 accumulation and
activity via the inhibition of MDM2-mediated p53 ubiquitination in
human lung cancer cells. Oncol Rep. 29:1983–1990. 2013.PubMed/NCBI
|
|
3
|
Park JS, Khoi PN, Joo YE, Lee YH, Lang SA,
Stoeltzing O, et al: EGCG inhibits recepteur d’origine nantais
expression by suppressing Egr-1 in gastric cancer cells. Int J
Oncol. 42:1120–1126. 2013.
|
|
4
|
Yiannakopoulou EC: Effect of green tea
catechins on breast carcinogenesis: a systematic review of in-vitro
and in-vivo experimental studies. Eur J Cancer Prev. Aug
9–2013.(Epub ahead of print).
|
|
5
|
Hagen RM, Chedea VS, Mintoff CP, Bowler E,
Morse HR and Ladomery MR: Epigallocatechin-3-gallate promotes
apoptosis and expression of the caspase 9a splice variant in PC3
prostate cancer cells. Int J Oncol. 43:194–200. 2013.PubMed/NCBI
|
|
6
|
Kim SO and Kim MR: (-)-Epigallocatechin
3-gallate inhibits invasion by inducing the expression of Raf
kinase inhibitor protein in AsPC1 human pancreatic adenocarcinoma
cells through the modulation of histone deacetylase activity. Int J
Oncol. 42:349–358. 2013.
|
|
7
|
Chen H, Landen CN, Li Y, Alvarez RD and
Tollefsbol TO: Enhancement of cisplatin-mediated apoptosis in
ovarian cancer cells through potentiating G2/M arrest and p21
upregulation by combinatorial epigallocatechin gallate and
sulforaphane. J Oncol. 2013:8729572013. View Article : Google Scholar
|
|
8
|
Kochi T, Shimizu M, Terakura D, Baba A,
Ohno T, Kubota M, et al: Non-alcoholic steatohepatitis and
preneoplastic lesions develop in the liver of obese and
hypertensive rats: suppressing effects of EGCG on the development
of liver lesions. Cancer Lett. 42:60–69. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ogawa K, Hara T, Shimizu M, Nagano J, Ohno
T, Hoshi M, et al: (-)-Epigallocatechin gallate inhibits the
expression of indoleamine 2,3-dioxygenase in human colorectal
cancer cells. Oncol Lett. 4:546–550. 2012.PubMed/NCBI
|
|
10
|
Chiou YS, Sang S, Cheng KH, Ho CT, Wang YJ
and Pan MH: Peracetylated (-)-epigallocatechin-3-gallate (AcEGCG)
potently prevents skin carcinogenesis by suppressing the
PKD1-dependent signaling pathway in CD34+ skin stem
cells and skin tumors. Carcinogenesis. 34:1315–1322. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shimizu M, Adachi S, Masuda M, Kozawa O
and Moriwaki H: Cancer chemoprevention with green tea catechins by
targeting receptor tyrosine kinases. Mol Nutr Food Res. 55:832–843.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fujiki H and Suganuma M: Green tea: an
effective synergist with anticancer drugs for tertiary cancer
prevention. Cancer Lett. 324:119–125. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Surh YJ: Cancer chemoprevention with
dietary phytochemicals. Nat Rev Cancer. 3:768–780. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Singh BN, Shankar S and Srivastava RK:
Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms,
perspectives and clinical applications. Biochem Pharmacol.
82:1807–1821. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Han W and Lo HW: Landscape of EGFR
signaling network in human cancers: biology and therapeutic
response in relation to receptor subcellular locations. Cancer
Lett. 318:124–134. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tebbutt N, Pedersen MW and Johns TG:
Targeting the ERBB family in cancer: couples therapy. Nat Rev
Cancer. 13:663–673. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kolch W and Pitt A: Functional proteomics
to dissect tyrosine kinase signalling pathways in cancer. Nat Rev
Cancer. 10:618–629. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Avraham R and Yarden Y: Feedback
regulation of EGFR signalling: decision making by early and delayed
loops. Nat Rev Mol Cell Biol. 12:104–117. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Marti U, Burwen SJ, Wells A, Barker ME,
Huling S, Feren AM, et al: Localization of epidermal growth factor
receptor in hepatocyte nuclei. Hepatology. 13:15–20. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Brand TM, Iida M, Luthar N, Starr MM,
Huppert EJ and Wheeler DL: Nuclear EGFR as a molecular target in
cancer. Radiother Oncol. 108:370–377. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lo HW, Hsu SC, Ali-Seyed M, Gunduz M, Xia
W, Wei Y, et al: Nuclear interaction of EGFR and STAT3 in the
activation of the iNOS/NO pathway. Cancer Cell. 7:575–589. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hanada N, Lo HW, Day CP, Pan Y, Nakajima Y
and Hung MC: Co-regulation of B-Myb expression by E2F1 and EGF
receptor. Mol Carcinog. 45:10–17. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hung LY, Tseng JT, Lee YC, Xia W, Wang YN,
Wu ML, et al: Nuclear epidermal growth factor receptor (EGFR)
interacts with signal transducer and activator of transcription 5
(STAT5) in activating Aurora-A gene expression. Nucleic Acids Res.
36:4337–4351. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dittmann K, Mayer C, Fehrenbacher B,
Schaller M, Raju U, Milas L, et al: Radiation-induced epidermal
growth factor receptor nuclear import is linked to activation of
DNA-dependent protein kinase. J Biol Chem. 280:31182–31189. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
|
|
26
|
Katlic MR, Facktor MA, Berry SA, McKinley
KE, Bothe A Jr and Steele GD Jr: ProvenCare lung cancer: a
multi-institutional improvement collaborative. CA Cancer J Clin.
61:382–396. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ramalingam SS, Owonikoko TK and Khuri FR:
Lung cancer: new biological insights and recent therapeutic
advances. CA Cancer J Clin. 61:91–112. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Herbst RS, Heymach JV and Lippman SM: Lung
cancer. N Engl J Med. 359:1367–1380. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Herbst RS, Fukuoka M and Baselga J:
Gefitinib - a novel targeted approach to treating cancer. Nat Rev
Cancer. 4:956–965. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Janku F, Stewart DJ and Kurzrock R:
Targeted therapy in non-small-cell lung cancer - is it becoming a
reality? Nat Rev Clin Oncol. 7:401–414. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tao Y, Song X, Deng X, Xie D, Lee LM, Liu
Y, et al: Nuclear accumulation of epidermal growth factor receptor
and acceleration of G1/S stage by Epstein-Barr-encoded oncoprotein
latent membrane protein 1. Exp Cell Res. 303:240–251. 2005.
View Article : Google Scholar
|
|
32
|
Shi Y, Tao Y, Jiang Y, Xu Y, Yan B, Chen
X, et al: Nuclear epidermal growth factor receptor interacts with
transcriptional intermediary factor 2 to activate cyclin D1 gene
expression triggered by the oncoprotein latent membrane protein 1.
Carcinogenesis. 33:1468–1478. 2012. View Article : Google Scholar
|
|
33
|
Sato M, Shames DS, Gazdar AF and Minna JD:
A translational view of the molecular pathogenesis of lung cancer.
J Thorac Oncol. 2:327–343. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shimizu M, Shirakami Y and Moriwaki H:
Targeting receptor tyrosine kinases for chemoprevention by green
tea catechin, EGCG. Int J Mol Sci. 9:1034–1049. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Masuda M, Suzui M and Weinstein IB:
Effects of epigallocatechin-3-gallate on growth, epidermal growth
factor receptor signaling pathways, gene expression, and
chemosensitivity in human head and neck squamous cell carcinoma
cell lines. Clin Cancer Res. 7:4220–4229. 2001.PubMed/NCBI
|
|
36
|
Hou Z, Sang S, You H, Lee MJ, Hong J, Chin
KV, et al: Mechanism of action of (-)-epigallocatechin-3-gallate:
auto-oxidation-dependent inactivation of epidermal growth factor
receptor and direct effects on growth inhibition in human
esophageal cancer KYSE 150 cells. Cancer Res. 65:8049–8056.
2005.
|
|
37
|
Adachi S, Nagao T, Ingolfsson HI, Maxfield
FR, Andersen OS, Kopelovich L, et al: The inhibitory effect of
(-)-epigallocatechin gallate on activation of the epidermal growth
factor receptor is associated with altered lipid order in HT29
colon cancer cells. Cancer Res. 67:6493–6501. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Milligan SA, Burke P, Coleman DT, Bigelow
RL, Steffan JJ, Carroll JL, et al: The green tea polyphenol EGCG
potentiates the antiproliferative activity of c-Met and epidermal
growth factor receptor inhibitors in non-small cell lung cancer
cells. Clin Cancer Res. 15:4885–4894. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Adachi S, Shimizu M, Shirakami Y, Yamauchi
J, Natsume H, Matsushima-Nishiwaki R, et al: (-)-Epigallocatechin
gallate downregulates EGF receptor via phosphorylation at
Ser1046/1047 by p38 MAPK in colon cancer cells. Carcinogenesis.
30:1544–1552. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Arteaga CL: Epidermal growth factor
receptor dependence in human tumors: more than just expression?
Oncologist. 7(Suppl 4): S31–S39. 2002. View Article : Google Scholar : PubMed/NCBI
|
